Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
PLoS One. 2022 Dec 2;17(12):e0278707. doi: 10.1371/journal.pone.0278707. eCollection 2022.
The purpose of this prospective study was to investigate changes in longitudinal parameters after stereotactic radiotherapy for lung cancer and to identify possible pretreatment factors related to radiation-induced lung toxicity and the decline in pulmonary function after radiotherapy.
Protocol-specified examinations, including 4-D CT, laboratory tests, pulmonary function tests (PFTs) and body composition measurements, were performed before SRT and at 1 month, 4 months and 12 months after stereotactic radiotherapy. Longitudinal differences were tested by using repeated-measures analysis of variance. Correlations were examined by using the Pearson product-moment correlation coefficient (r).
Sixteen patients were analyzed in this study. During a median follow-up period of 26.6 months, grade 1 and 2 lung toxicity occurred in 11 patients and 1 patient, respectively. The mean Hounsfield units (HU) and standard deviation (SD) of the whole lung, as well as sialylated carbohydrate antigen KL-6 (KL-6) and surfactant protein-D (SP-D), peaked at 4 months after radiotherapy (p = 0.11, p<0.01, p = 0.04 and p<0.01, respectively). At 4 months, lung V20 Gy (%) and V40 Gy (%) were correlated with changes in SP-D, whereas changes in the mean HU of the lung were related to body mass index and lean body mass index (r = 0.54, p = 0.02; r = 0.57, p = 0.01; r = 0.69, p<0.01; and r = 0.69, p<0.01, respectively). The parameters of PFTs gradually declined over time. When regarding the change in PFTs from pretreatment to 12 months, lung V5 Gy (cc) showed significant correlations with diffusion capacity for carbon monoxide (DLCO), DLCO/alveolar volume and the relative change in DLCO (r = -0.72, p<0.01; r = -0.73, p<0.01; and r = -0.63, p = 0.01, respectively).
The results indicated that some parameters peaked at 4 months, but PFTs were the lowest at 12 months. Significant correlations between lung V5 Gy (cc) and changes in DLCO and DLCO/alveolar volume were observed.
本前瞻性研究旨在探讨肺癌立体定向放疗后纵向参数的变化,并确定与放疗后肺毒性和肺功能下降相关的可能的预处理因素。
在立体定向放疗前、放疗后 1 个月、4 个月和 12 个月时,进行了协议规定的检查,包括 4DCT、实验室检查、肺功能检查(PFT)和身体成分测量。使用重复测量方差分析测试纵向差异。使用 Pearson 积矩相关系数(r)检验相关性。
本研究分析了 16 例患者。在中位随访 26.6 个月期间,11 例患者出现 1 级和 2 级肺毒性,1 例患者出现 1 级肺毒性。放疗后 4 个月时,全肺平均 Hounsfield 单位(HU)和标准差(SD)、唾液酸化糖链抗原 KL-6(KL-6)和表面活性蛋白-D(SP-D)均达到峰值(p=0.11,p<0.01,p=0.04 和 p<0.01)。4 个月时,肺 V20Gy(%)和 V40Gy(%)与 SP-D 的变化相关,而肺 HU 的变化与体重指数和瘦体重指数相关(r=0.54,p=0.02;r=0.57,p=0.01;r=0.69,p<0.01;r=0.69,p<0.01)。PFT 逐渐随时间下降。当将从治疗前到 12 个月的 PFT 变化作为观察指标时,肺 V5Gy(cc)与一氧化碳弥散量(DLCO)、DLCO/肺泡容积和 DLCO 的相对变化显著相关(r=-0.72,p<0.01;r=-0.73,p<0.01;r=-0.63,p=0.01)。
结果表明,一些参数在 4 个月时达到峰值,但 PFT 在 12 个月时最低。观察到肺 V5Gy(cc)与 DLCO 和 DLCO/肺泡容积的变化之间存在显著相关性。